Contact Support +1-(281)-619-8646
Free Addition on COVID-19 Impact Analysis                        Upto 15% Discounts for all Research Reports
Report Store

Market Research Services and Market Research

Anti-Idiopathic Pulmonary Fibrosis Drugs Market

Anti-Idiopathic Pulmonary Fibrosis Drugs Market
  • MMC001219
  • Category: Healthcare & Life Sciences
  • Nov.2024
  • Publisher id : Meridian Market Consultants
  • No. of pages : 200
  • Rating :
  • Format : PDF,PPT

    
    
    


  • Report Description
  • Table Of Content
  • Request Sample

Anti-Idiopathic Pulmonary Fibrosis Drugs Market

The report is titled as ‘Anti-Idiopathic Pulmonary Fibrosis Drugs Market: Opportunity Analysis and Future Assessment 2020-2028’. The global anti-idiopathic pulmonary fibrosis drugs market in 2020 is estimated for more than US$ 2,730.5 Mn and expected to reach a value of US$ 10,194.4 Mn by 2028 with a significant CAGR of 18.1%.

Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation

Anti-idiopathic pulmonary fibrosis drugs market includes segments such as marketed drugs, innovator and off-label drugs, mechanism of action. The mechanism of action further divided into five other categories such as anti-fibrotic, tyrosine kinase inhibitors, anti-inflammatory drugs, immunosuppressants, and others.

The drug type segment further divided into two other categories such as innovator drugs, and off-label drugs.

Anti-fibrotic, Tyrosine Kinase Inhibitors, Anti-incendiary Drugs, Immunosuppressant, Other MoA, Innovator Drugs, Generics market report demonstrates precious for anybody needing to more readily comprehend the business and its fundamental elements. It demonstrates helpful for organizations who wish to venture into various segments or investigate another area for development of their current tasks. 

Anti-Idiopathic Pulmonary Fibrosis Drugs Market Key Players

Anti-idiopathic pulmonary fibrosis drugs market is mainly dominated by Roche Holding AG, Boehringer Ingelheim GmbH, Shionogi & Co., Ltd., Merck & Co., Cipla Limited, Galapagos NV and MediciNova Inc. Some of the other key participating players in anti-idiopathic pulmonary fibrosis drugs market are Actelion Pharmaceuticals, Afferent Pharmaceuticals, Asahi Kasei Pharma, Bellerophon Therapeutics, Biogen, FibroGen, Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, and Kadmon Pharmaceuticals and others.

Anti-Idiopathic Pulmonary Fibrosis Drugs Market Regional Overview

On the basis of region, the anti-idiopathic pulmonary fibrosis drugs market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America Drug Discovery Outsourcing market is expected to be the most dominating market throughout the forecast period due to an increasing number of pharmaceutical companies and research institutes in the U.S. Whereas, Europe will maintain its second-largest position with Germany and U.K being the most attractive markets within the region.

MMC Overview on Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the Adsorbents market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Adsorbents

•    Advantage of Adsorbents over other modalities

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.

1.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Snapshot

2.4.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Mechanism of Action

3.1.2.    BPS Analysis, By Mechanism of Action

3.2.    Market Revenue (US$Mn) Forecast, By Mechanism of Action

3.2.1.    Anti-fibrotics

3.2.2.    Tyrosine kinase inhibitors

3.2.3.    Anti-inflammatory Drugs

3.2.4.    Immunosuppressant

3.2.5.    Others

3.3.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Attractiveness Index, By Mechanism of Action

4.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Drugs

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Drugs

4.1.2.    BPS Analysis, By Drugs

4.2.    Market Revenue (US$Mn) Forecast, By Drugs

4.2.1.    Innovator Drugs

4.2.1.1.    Ofev

4.2.1.2.    Esbriet

4.2.1.3.    Future Brand Drugs

4.2.2.    Off-Label Drugs

5.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Region

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Region

5.1.2.    BPS Analysis, By Region

5.2.    Market Revenue (US$Mn) Forecast, By Region

5.2.1.    North America

5.2.2.    Latin America

5.2.3.    Europe

5.2.4.    Asia Pacific

5.2.5.    Middle East

5.2.6.    Africa

5.3.    Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Attractiveness Index, By Region

6.    North America Anti-Idiopathic Pulmonary Fibrosis Drugs Market Analysis and Forecast, 2020–2028

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Country

6.1.2.    BPS Analysis, By Country

6.2.    Market Revenue (US$Mn) Forecast, By Country

6.2.1.    U.S. Anti-Idiopathic Pulmonary Fibrosis Drugs Market

6.2.2.    Canada Anti-Idiopathic Pulmonary Fibrosis Drugs Market

6.3.    North America Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action

6.3.1.    Anti-fibrotics

6.3.2.    Tyrosine kinase inhibitors

6.3.3.    Anti-inflammatory Drugs

6.3.4.    Immunosuppressant

6.3.5.    Others

6.4.    North America Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Drugs

6.4.1.    Innovator Drugs

6.4.1.1.    Ofev

6.4.1.2.    Esbriet

6.4.1.3.    Future Brand Drugs

6.4.2.    Off-Label Drugs

6.5.    North America Anti-Idiopathic Pulmonary Fibrosis Drugs Market Attractiveness Index

6.5.1.    By Country

6.5.2.    By Drugs

6.5.3.    By Mechanism of Action

7.    Latin America Anti-Idiopathic Pulmonary Fibrosis Drugs Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market (US$Mn) Forecast, By Country

7.2.1.    Brazil Anti-Idiopathic Pulmonary Fibrosis Drugs Market

7.2.2.    Mexico Anti-Idiopathic Pulmonary Fibrosis Drugs Market

7.2.3.    Argentina Anti-Idiopathic Pulmonary Fibrosis Drugs Market

7.2.4.    Rest of Latin America Anti-Idiopathic Pulmonary Fibrosis Drugs Market

7.3.    Latin America Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action

7.3.1.    Anti-fibrotics

7.3.2.    Tyrosine kinase inhibitors

7.3.3.    Anti-inflammatory Drugs

7.3.4.    Immunosuppressant

7.4.    Latin America Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Drugs

7.4.1.    Innovator Drugs

7.4.1.1.    Ofev

7.4.1.2.    Esbriet

7.4.1.3.    Future Brand Drugs

7.4.2.    Off-Label Drugs

7.5.    Attractiveness Index

7.5.1.    By Country

7.5.2.    By Drugs

7.5.3.    By Mechanism of Action

8.    Europe Anti-Idiopathic Pulmonary Fibrosis Drugs Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    U.K. Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.2.    Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.3.    Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.4.    France Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.5.    Spain Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.6.    Russia Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.7.    Poland Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.8.    BENELUX Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.9.    NORDIC Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.2.10.    Rest of Europe Anti-Idiopathic Pulmonary Fibrosis Drugs Market

8.3.    Europe Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action

8.3.1.    Anti-fibrotics

8.3.2.    Tyrosine kinase inhibitors

8.3.3.    Anti-inflammatory Drugs

8.3.4.    Immunosuppressant

8.4.    Europe Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Drugs

8.4.1.    Innovator Drugs

8.4.1.1.    Ofev

8.4.1.2.    Esbriet

8.4.1.3.    Future Brand Drugs

8.4.2.    Off-Label Drugs

8.5.    Europe Anti-Idiopathic Pulmonary Fibrosis Drugs Market Attractiveness Index

8.5.1.    By Country

8.5.2.    By Drugs

8.5.3.    By Mechanism of Action

9.    Asia Pacific Anti-Idiopathic Pulmonary Fibrosis Drugs Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    China Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.2.2.    India Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.2.3.    Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.2.4.    Australia and New Zealand Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.2.5.    South Korea Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.2.6.    ASEAN Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.2.7.    Rest of Asia Pacific Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.3.    Asia Pacific Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action

9.3.1.    Anti-fibrotics

9.3.2.    Tyrosine kinase inhibitors

9.3.3.    Anti-inflammatory Drugs

9.3.4.    Immunosuppressant

9.4.    Asia Pacific Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Drugs

9.4.1.    Innovator Drugs

9.4.1.1.    Ofev

9.4.1.2.    Esbriet

9.4.1.3.    Future Brand Drugs

9.4.2.    Off-Label Drugs

9.5.    Asia Pacific Anti-Idiopathic Pulmonary Fibrosis Drugs Market Attractiveness Index

9.5.1.    By Country

9.5.2.    By Mechanism of Action

10.    Middle East Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Region

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    GCC Countries Anti-Idiopathic Pulmonary Fibrosis Drugs Market

10.2.2.    Israel Anti-Idiopathic Pulmonary Fibrosis Drugs Market

10.2.3.    Oman Anti-Idiopathic Pulmonary Fibrosis Drugs Market

10.2.4.    Rest of Middle East Anti-Idiopathic Pulmonary Fibrosis Drugs Market

10.3.    Middle East Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action

10.3.1.    Anti-fibrotics

10.3.2.    Tyrosine kinase inhibitors

10.3.3.    Anti-inflammatory Drugs

10.3.4.    Immunosuppressant

10.4.    Middle East Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Drugs

10.4.1.    Innovator Drugs

10.4.1.1.    Ofev

10.4.1.2.    Esbriet

10.4.1.3.    Future Brand Drugs

10.4.2.    Off-Label Drugs

10.5.    Middle East Anti-Idiopathic Pulmonary Fibrosis Drugs Market Attractiveness Index

10.5.1.    By Country

10.5.2.    By Drugs

10.5.3.    By Mechanism of Action

11.    Africa Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    South Africa Anti-Idiopathic Pulmonary Fibrosis Drugs Market

11.2.2.    Egypt Anti-Idiopathic Pulmonary Fibrosis Drugs Market

11.2.3.    North Africa Anti-Idiopathic Pulmonary Fibrosis Drugs Market

11.2.4.    Rest of Africa Anti-Idiopathic Pulmonary Fibrosis Drugs Market

11.3.    Africa Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action

11.3.1.    Anti-fibrotics

11.3.2.    Tyrosine kinase inhibitors

11.3.3.    Anti-inflammatory Drugs

11.3.4.    Immunosuppressant

11.4.    Africa Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Drugs

11.4.1.    Innovator Drugs

11.4.1.1.    Ofev

11.4.1.2.    Esbriet

11.4.1.3.    Future Brand Drugs

11.4.2.    Off-Label Drugs

11.5.    Africa Anti-Idiopathic Pulmonary Fibrosis Drugs Market Attractiveness Index

11.5.1.    By Country

11.5.2.    By Drugs

11.5.3.    By Mechanism of Action

12.    Recommendation

12.1.    Market Strategy

13.    Competitive Landscape

13.1.    Competition Dashboard

13.2.    List and Company Overview of Global Key Players

13.3.    Company Profiles

13.3.1.    Roche Holding AG

13.3.1.1.    Company Overview

13.3.1.2.    Financial Overview

13.3.1.3.    Product Portfolio

13.3.1.4.    Key Developments

13.3.1.5.    Business Strategies

13.3.2.    Boehringer Ingelheim GmbH

13.3.3.    Shionogi & Co., Ltd.

13.3.4.    Merck & Co.

13.3.5.    Cipla Limited

13.3.6.    Galapagos NV

13.3.7.    MediciNova Inc.

14.    Acronyms

Frequently Asked Questions

  • What is the projected market size & Compound Annual Growth Rate (CAGR) of the market?
    The global anti-idiopathic pulmonary fibrosis drugs market in 2020 is estimated for more than US$ 2,730.5 Mn and expected to reach a value of US$ 10,194.4 Mn by 2028 with a significant CAGR of 18.1%.
  • What includes in mechanism of action segment of market?
    The mechanism of action further divided into five other categories such as anti-fibrotic, tyrosine kinase inhibitors, anti-inflammatory drugs, immunosuppressants, and others.
  • What segments are covered in market report?
    Anti-idiopathic pulmonary fibrosis drugs market includes segments such as marketed drugs, innovator and off-label drugs, mechanism of action.
  • What are the key participating players in the market?
    Roche Holding AG, Boehringer Ingelheim GmbH, Shionogi & Co., Ltd., Merck & Co., Cipla Limited, Galapagos NV and MediciNova Inc. Some of the other key participating players in anti-idiopathic pulmonary fibrosis drugs market are Actelion Pharmaceuticals, Afferent Pharmaceuticals, Asahi Kasei Pharma, Bellerophon Therapeutics, Biogen, FibroGen, Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, and Kadmon Pharmaceuticals are the key participating players in the market